Hypoxia-inducible factor-1α (HIF-1α), a member of the transcription family characterized by a basic helix-loop-helix (bHLH) domain and a PAS domain, regulates the transcription of hypoxia-inducible genes involved in erythropoiesis, vascular remodelling and glucose\energy metabolism. It contains bHLH\ PAS domains in the N-terminal half, and a nuclear localization signal (NLS) and two transactivation domains (TADs) in the Cterminal half. It also has an oxygen-dependent degradation (ODD) domain, which is required to degrade HIF-1α protein by the ubiquitin-proteasome pathway. In this study, we identified a new alternatively spliced variant of human HIF-1α mRNA, which lacked both exons 11 and 12, producing a frame shift and giving a shorter form of HIF-1α. In the corresponding protein, a part of the ODD domain, both TADs and the C-terminal NLS motif were missing. Expression of endogenous HIF-1α variant protein was identified using immunoprecipitation and immuno-
INTRODUCTION
Mammalian cells up-regulate the expression of hypoxic genes in order to survive in hypoxic conditions. The hypoxia-induced proteins are involved in glucose\energy metabolism, vascular development\remodelling, vasodilation and erythropoiesis [1, 2] . The hypoxic induction of these genes depends on a basic helixloop-helix (bHLH) transcription factor, hypoxia-inducible factor 1 (HIF-1), which is activated by hypoxia and binds to a consensus sequence (5h-RCGTG-3h) in the hypoxia-response elements [3, 4] . HIF-1 is composed of HIF-1α and arylhydrocarbon receptor nuclear translocator (ARNT). They both belong to the PAS family of bHLH transcription factors [5] . Normally, HIF-1 activity depends on the amount of HIF-1α protein, which is increased markedly by hypoxia, whereas ARNT protein is present constitutively regardless of oxygen tension. Under normoxic conditions, the de no o-synthesized HIF-1α protein is immediately degraded by the ubiquitin-proteasome pathway. However, under hypoxic conditions, it escapes from the degradation process and imports into the nucleus, where it co-dimerizes with ARNT. It binds to the hypoxia-response elements of hypoxia-inducible genes and transactivates these genes [6, 7] .
HIF-1α is an 826-amino-acid protein that is unique to HIF-1, whereas ARNT is a common transcription factor to be dimerized with the arylhydrocarbon receptor and other bHLH\PAS proteins [5] . The N-terminal half of HIF-1α contains the bHLH and PAS domains, which are essential for dimerization and DNA binding [8] . The C-terminal half contains two transactivation domains (TADs), which are localized to amino acid residues 531-575 for N-terminal TAD and 786-826 for C-terminal TAD [9] . Two nuclear localization signals (NLSs) are localized in the N-terminal (amino acids 17-74) and C-terminal (amino acids 718-721) regions. Although both NLSs have been identified as determining the nuclear localization of HIF-1α, the C-terminal NLS motif is considered to be more important in the nuclear translocation induced by hypoxia [10] . HIF-1α contains a unique oxygen-dependent degradation (ODD) domain, which is localized to amino acid residues 401-603 [6] . The whole ODD domain might be required for the ubiquitin\proteasome-dependent degradation of HIF-1α, because HIF-1α remains stable even under normoxic conditions when part of the ODD domain is deleted. Recently, the subdomains in the ODD domain have been analysed intensively in an attempt to understand the mechanism of oxygen-dependent regulation of HIF-1α stability. Under normoxic conditions, von Hippel-Lindau tumour suppressor protein (pVHL), one of multiprotein ubiquitin E3 ligase complex, mediates the ubiquitylation of HIF-1α, which becomes the target of proteasomal proteolysis [11] . In this process, the N-terminal (380-417) and the C-terminal (556-572) sites of the ODD domain are minimal subdomains interacting with pVHL, and the hydroxylation of two proline residues (Pro-402 and Pro-564) in these subdomins determines pVHL binding to HIF-1α [12] [13] [14] . However, under hypoxic conditions, the proline hydroxylation is inhibited and then HIF-1α becomes stable.
Several alternatively spliced variants of HIF-1α mRNA have been previously found in mouse, rat and human cells. Two splicing events in mouse cells have been described with alternative translation start sites [15] and alternative splicing within exon 10 [16] . The alternative splicing in rat cells occurred at the Nterminal end of HIF-1α [17] . In human cells, two splicing events were described with alternative splicing between exons 1 and 2 and also between exons 13 and 14 [18] . The former variant had an additional 3 bp at the junction of exons 1 and 2 without a frame shift. The latter had lost exon 14, resulting in a frame shift and an immediate termination codon. Because the latter had most of the essential domains of HIF-1α conserved, it showed oxygen-tension-dependent regulation and the transactivation by the vascular endothelial growth factor (VEGF) promoter.
In this study, we identified a new splicing variant of HIF-1α mRNA in human cells. The new variant differs from the HIF-1α mRNA by lacking exons 11 and 12, which produces a frame shift and introduces a shorter form of HIF-1α. The deduced protein contains bHLH\PAS domains and the N-terminal NLS motif, but is deprived of a part of the ODD domain, both the TADs and the C-terminal NLS motif. The expressed HIF-1α isoform exhibited neither transactivation activity nor hypoxiainduced nuclear translocation. In contrast with HIF-1α, the expressed protein was strikingly stable under normoxic conditions and was up-regulated by hypoxia, cobalt ions and desferrioxamine to a smaller degree. We also demonstrated that the HIF-1α isoform competed with endogenous HIF-1α and suppressed HIF-1 activity, resulting in the down-regulation of mRNA expression of hypoxia-inducible genes.
EXPERIMENTAL

Cell culture
Most cancer cell lines were obtained from the A.T.C.C., but the SNU-601 cell line, a stomach cancer cell line, was obtained from the Korean Cell Line Bank (Seoul, South Korea). Hep3B cells were cultured in α-modified Eagle's medium (Gibco BRL). HEK-293, HeLa and SNU-601, and the murine cell lines NIH 3T3 and CT-26, were cultured in Dulbecco's modified Eagle's medium (Gibco BRL). Both culture media were supplemented with 10 % heat-inactivated fetal calf serum (Gibco BRL), 100 units\ml penicillin and 100 µg\ml streptomycin in a humidified atmosphere containing 5 % CO # at 37 mC. Oxygen tensions in the incubator (model 9108MS2 ; Vision Sci Co., Seoul, South Korea) were either 140 mmHg (20 % O # , v\v ; normoxia) or 7 mmHg (1 % O # , v\v ; hypoxia).
Cloning and sequencing of a human HIF-1α cDNA isoform
An isoform of HIF-1α cDNA was cloned by reverse transcriptase PCR (RT-PCR). RNAs extracted from HEK-293 cells were reverse transcribed using the avian myeloblastosis virus reverse transcriptase system (Promega). This template was amplified using five pairs of PCR primers designed as shown in Figure  1 (A). The nucleotide sequences of the primers are summarized in Table 1 . The resulting PCR products of the HIF-1α cDNAs were extracted from agarose gels and cloned using a pCR2.1-TOPO cloning kit (Invitrogen). The plasmids containing the isoform were amplified, purified and analysed for DNA sequencing.
RT-PCR of mRNAs for HIF-1α and hypoxia-inducible genes
For identification and quantification of the HIF-1α variant mRNA and the mRNAs of hypoxia-inducible genes, a highly sensitive, semi-quantitative RT-PCR was performed as described previously [19] . Total RNAs were isolated from the cultured cells using Trizol (Gibco BRL 
Expression plasmids and transfection
A haemagglutinin (HA)-tagged HIF-1α variant expression plasmid was made using a PCR-based mutagenesis kit (Stratagene). The mutagenesis with specific oligonucleotides (sense, 5h-AACT-ACAGTTCCAGAGGAAGAACTAA-3h ; antisense, 5h-CTCA-GGTGAACTTTGTCTAGT-3h) was employed to delete nucleotides derived from exons 11 and 12. The fidelity of the PCR and the identity of the construct were confirmed by sequencing the insert. For transient transfection, about 40 % of the confluent HEK-293 cells in 60 mm cell-culture dishes were transfected with 4 µg of pcDNA3, pcDNA3-HIF-1α or pcDNA3-HIF-1α variant using the calcium phosphate method as described previously [20] .
Reporter assays
The erythropoietin (EPO)-and VEGF-enhancer-driven luciferase reporter genes were constructed as described previously [20] . The synthetic DNAs encoding HIF-1-binding enhancer regions (EPO, 5h-GGTACCGGCCCTACGTGCTGTCTCACACAGCCTG-TCTGACCTCTCGACCTACCGGCCAGATCT-3h ; VEGF, 5h-GTACCCACAGTGCATACGTGGGCTCCAACAGGTCC-TCTTGATC-3h) were inserted into the pGL3 promoter plasmid (Promega). To assay HIF-1 activity, HEK-293 cells were cotransfected with 5 µg each of luciferase reporter gene and the plasmid cytomegalovirus-β-gal for each 100 mm dish, using the calcium phosphate method. Transfected cells were split into nine aliquots and incubated for 42 h. After stabilizing, the cells were incubated for 16 h in 20 % or 1 % O # (normoxia or hypoxia, respectively). Cells were lysed and assayed for luciferase activity using a Biocounter M1500 luminometer (Lumac). β-Galactosidase assays were performed for normalization of transfection efficiency.
Preparations of nuclear and cytosolic proteins
Cells were cooled quickly by placing the plates on ice and were then washed twice in ice-cold PBS. Scraped cells were centrifuged at 1000 g for 5 min at 4 mC and then washed twice with PBS. They were resuspended in a lysis buffer containing 0.2 % Nonidet P-40, and the nuclear and cytosolic proteins were extracted as described previously [20] .
Electrophoretic mobility-shift assay (EMSA)
The oligonucleotide probe used in the gel shift assay for HIF-1 consisted of the sequence 5h-ACCGGCCCTACGTGCTGTCT-CAC-3h. The $#P-labelled double-stranded probe was prepared Dominant-negative isoform of human hypoxia-inducible factor-1α and EMSA was performed as described previously [20] . DNAprotein binding reactions were carried out for 20 min at 4 mC and run on 5 % non-denaturing polyacrylamide gels. For supershift analysis, 1 µl of a rabbit HIF-1α antiserum was added to the completed EMSA reaction mixture and incubated for 2 h at 4 mC prior to loading.
Immunoblotting and immunoprecipitation
For immunoblotting of the HIF-1α and its variant protein, 20 µg of cell extract was separated on SDS\6 % and 10 % polyacrylamide gels, respectively, and transferred to an Immobilon-P membrane (Millipore). Immobilized proteins were incubated overnight at 4 mC with a rabbit anti-HIF-1α antibody, diluted 1 : 1000, with 5 % skimmed milk in Tris-buffered saline containing 0.1 % Tween-20 (TTBS). Horseradish peroxidaseconjugated anti-rabbit antiserum (Amersham Bioscience) was used as a secondary antibody (1 : 5000 dilution in 5 % skimmed milk in TTBS). After extensive washing with TTBS, the complexes were visualized using Enhanced Chemiluminiscence Plus (Amersham Bioscience). HIF-1 antiserum was generated in rabbits against a bacterially expressed fragment encompassing amino acids 418-698 of human HIF-1α as described previously [19] . For immunoprecipitation of endogenous HIF-1α variant protein, HEK-293 cells were treated with 130 µM desferrioxamine for 8 h or 10 µM N-carbobenzoxyl-Leu-Leu-Leu-al (CBZ-LLL) for 18 h. The cell lysates were incubated with the rabbit HIF-1α antiserum or a preimmune rabbit serum, followed by incubation with Protein A-Sepharose beads (Amersham Bioscience). After washing, the immunocomplexes were eluted by boiling for 3 min in SDS sample buffer containing 10 mM dithiothreitol, and then subjected to SDS\PAGE. Immunoblotting using a rat anti-HIF-1α antibody was performed as described previously [20] . For co-immunoprecipitation of HIF-1α variant and ARNT, cells were were co-transfected with the HA-HIF-1α variant and ARNT expression plasmids. After 48 h of incubation, the cytosolic proteins were prepared as described previously [20] . The HA-tagged HIF-1α variant was immunoprecipitated with a rabbit anti-HA antibody (Santa Cruz Biotechnology) and then the co-immunoprecipitation of ARNT was identified with a goat anti-ARNT antibody (Santa Cruz Biotechnology) using Western blotting.
Immunofluorescence microscopy
HEK-293 cells transfected with pcDNA3-HA-HIF-1α variant were subjected to hypoxia for 4 h, and fixed with 4 % paraformaldehyde in PBS at room temperature for 15 min. The cells were washed three times with 100 mM glycine in PBS, permeabilized with 0.1 % Triton X-100 in PBS for 1 min and washed three times with PBS. After blocking non-specific binding with 5 % normal goat serum in PBS for 1 h, the cells were incubated overnight at 4 mC with the rabbit anti-HIF-1α antibody (1 : 1000) or the rabbit anti-HA antibody (1 : 250), purchased from Santa Cruz Biotechnology. The primary antibodies were stained by incubation with FITC-conjugated goat anti-rabbit antibody (Jackson ImmunoResearch Laboratories) at room temperature for 1 h. After washing in PBS, the cells were analysed by confocal laser scanning microscopy (Bio-Rad MRC1024).
Figure 2 Schematic representation of the cloned HIF-1α isoform
The exons 10 and 13 were joined directly, which generated a new reading frame in the 13th exon. This alternative splicing introduced four new amino acids and an immediate termination codon. It translates into a 516-amino-acid polypeptide (HIF-1α 516 ), losing the ODD, TAD and the NLS domains. UTR, untranslated region ; A and B, PAS A and PAS B subdomains respectively.
RESULTS
Identification of an alternatively spliced variant of human HIF-1α mRNA
Five pairs of PCR primers were designed to identify the splicing of HIF-1α mRNA. Total RNAs extracted from the HEK-293 cells were reverse transcribed and amplified with specific primers. The RT-PCR products incorporated by [α-$#P]dCTP were electrophoresed and the dried gel was autoradiographed. Two distinct DNA bands of different sizes were observed reproducibly for both the RT-PCR 3 and RT-PCR 4 primers ( Figure 1B, lanes 3  and 4) . These PCR products were cloned and sequenced as described in the Experimental section. The lower PCR fragment in RT-PCR 3 was identified as having lost both exons 11 and 12 and as having been formed by a direct connection between exons 10 and 13, representing a new variant of HIF-1α cDNA. The lower PCR fragment in RT-PCR 4 was identified as having lost exon 14, which is identical with a variant reported previously [18] .
To confirm that the variant cDNA had no other splicing site than exons 11 and 12, the structures of HIF-1α cDNAs were analysed further using the other specific primers (RT-PCR 1 and 2). No other splicing was found between exons 1 and 10 ( Figure 1B , lanes 1 and 2). These results indicated that the new splicing HIF-1α variant loses exons 11 and 12 without additional splicing at any other exons. To compare the mRNA levels of HIF-1α and the variant, semi-quantitative RT-PCR using [α-$#P]dCTP and autoradiography was performed as described in the Experimental section. The HIF-1α variant was expressed ubiquitously in all human cell lines tested, whereas its expression was much lower in murine cell lines ( Figure 1C ). For quantification of these PCR fragments, each radioactive band was cut out from the dried gel and the radioactivities were measured using a β-counter. The relative amounts of variant mRNA are represented in Figure 1 (D) and were assessed by dividing the c.p.m. value of the variant fragment by that of the corresponding HIF-1α fragment. The approximate molar ratio of the variant to HIF-1α was calculated using the following equation : (c.p.m. of HIF-1α variant\c.p.m. of wildtype HIF-1α)i(705\148) (705 and 148 represent the numbers of nucleotides present in the wild-type and variant PCR products, respectively). The mean expression level of the variant mRNA in human cell lines was approx. 7.5 % of that of HIF-1α. However, the expression levels of the variant were much lower in the mouse cell lines, which suggests that the variant was expressed differently among species.
The structure of HIF-1α cDNA isoforms
The HIF-1α variant cDNA was cloned and sequenced as described in the Experimental section, and its structure is summarized in Figure 2 . The cloned cDNA was identical with the HIF-1α cDNA except for a 557 bp deletion in the middle. Reference to HIF-1α genomic organization [21] showed that the cloned cDNA was derived from an alternatively spliced mRNA that lacks both exons 11 and 12 of the HIF-1α gene (Figure 2) . In this mRNA, exons 10 and 13 were joined, generating a new reading frame after the site of the deletion and an immediate termination codon in exon 13. Consequently, this alternative splicing introduces four new amino acids, Asn-Tyr-Ser-Ser, as a new C-terminus following Glu&"# of the wild-type 826-amino acid HIF-1α protein. This novel form of HIF-1α mRNA translates into a 516-amino-acid polypeptide, which we designated HIF-1α&"'. Compared with HIF-1α, HIF-1α&"' conserves both bHLH and PAS domains, which are essential for the binding with ARNT. However, it loses the C-terminal pVHL-interacting subdomain (amino acids 556-572) in the ODD domain, TAD and NLS motif. Based on its structure, it is expected to be regulated partly by oxygen tension and to exhibit neither transactivation activity nor hypoxia-induced translocation into the nucleus.
Expression of HIF-1α 516 protein in HEK-293 cells
To identify endogenous HIF-1α&"' protein, immunoprecipitation of the protein was performed using two kinds of anti-HIF-1α antibody, raised in rabbit and rat. A broad band was observed in the immuoprecipiate samples pulled down by the anti-HIF-1α antibody, whereas no immunopositive band was detected in the sample treated with the preimmune serum. The intensity of the immunopositive band somehow increased in desferrioxaminetreated cells and increased markedly in cells treated with a proteasome inhibitor, CBZ-LLL, as shown in Figure 3(A) . The molecular size of the immunopositive protein was slightly less than that of the expressed HA-tagged HIF-1α&"' protein. This difference in molecular size was expected because HA-tagged HIF-1α&"' has the extra sequence associated with HA and the hinge peptides. The immunopositive protein might be endogenous HIF-1α&"' protein because its molecular size, protein band pattern and inducibility by desferrioxamine and CBZ-LLL were similar to those of expressed HIF-1α&"' shown in Figures 3(B) and 3(C). However, a direct comparison of the expression levels of endogenous HIF-1α&"' and wild-type HIF-1α is impossible because the antibodies used, made from an approx. 250-aminoacid peptide including exons 11 and 12, had lower antigenicity to HIF-1α&"' compared with wild-type HIF-1α. To characterize HIF-1α&"' protein, we transfected HEK-293 cells with 4 µg of the HA-tagged HIF-1α&"' expression plasmid. On an SDS\polyacrylamide gel the protein band was somewhat broad, and its molecular mass was analysed as being between 60 and 75 kDa ( Figure 3A ). This molecular mass is higher than the theoretical molecular mass (58.5 kDa) calculated using the compute pI\Mw program in ExPASy Proteomics tools, which suggests that the variant protein, like HIF-1α, may have been modified after translation. The HIF-1α&"' protein was present even under normoxic conditions. The HIF-1α&"' protein was induced mildly by CBZ-LLL (a proteasome inhibitor), hypoxia, desferrioxamine (an iron chelator) and cobalt ions ( Figure 3A ), but its fold induction was much lower than that of HIF-1α protein [19, 20] . Since the mechanism of HIF-1α degradation could be saturated by overexpressing HIF-1α&"', as in the case of overexpressed wild-type HIF-1α [22] , we reduced the dose of HIF-1α&"' plasmid to 1 µg ( Figure 3C ). The fold induction of HIF-1α&"' by hypoxia and cobalt was still lower than that of wild-type HIF-1α ( Figure 3D ). However, HIF-1α&"' was induced significantly by treatment with desferrioxamine. This HIF-1α&"' induction by desferrioxamine seems to be related to the remaining the N-terminal pVHL-interacting subdomain (amino acids 380-417) in the ODD domain of HIF-1α&"', but the role of the Nterminal subdomain in this desferrioxamine effect remains to be investigated.
To study the subcellular localization of HIF-1α&"', we measured HIF-1α and HIF-1α&"' in the cytosolic and nuclear fractions. HIF-1α&"' protein was present dominantly in the cytosolic fraction ( Figures 3F and 3G) , whereas HIF-α protein was present predominantly in the nucleus ( Figure 3E ). To confirm the subcellular localization of HIF-1α&"', we performed the immunocytochemistry, as shown in Figure 3 (H). HIF-1α&"' was localized to the cytoplasm, whereas wild-type HIF-1α was localized to the nucleus. These properties are a result of the loss of the ODD domain and NLS motif, as expected from its protein structure, shown in Figure 2 .
Inhibitory effect of HIF-1α
516 on HIF-1 activity
Since HIF-1α&"' protein has the same structure as HIF-1α in part, but lacks transcription-factor function, we considered the possibility that it works like a dominant-negative mutant of HIF-1α. To test this hypothesis, the effects of HIF-1α&"' on the expression of reporter genes, which are regulated by HIF-1, were examined. The transfected cells were co-transfected with reporter plasmids containing either EPO-or VEGF-enhancer elements fused to the luciferase gene. The luciferase activities of the EPO-enhancer reporter ( Figure 4A ) and VEGF-enhancer reporter ( Figure 4B ) increased in hypoxic pcDNA-transfected cells. To examine whether HIF-1α&"' competes with HIF-1α, increasing amounts Dominant-negative isoform of human hypoxia-inducible factor-1α of pHIF-1α&"' were co-transfected into pHIF-1α-tranfected cells with EPO or VEGF-enhancer reporter plasmids. The overexpressed HIF-1α exaggerated the hypoxic responses of the reporters, but the hypoxic responses were diminished markedly by HIF-1α&"' in a dose-dependent manner ( Figures 4A and 4B) . These results suggest that HIF-1α&"' competes with HIF-1α in terms of HIF-1 activity in a manner similar to a dominant-negative mutant.
Inhibitory effect of HIF-1α 516 on HIF-1 binding to the hypoxiaresponse element
To examine whether HIF-1α&"' inhibits the DNA binding of endogenous HIF-1 to the hypoxia-response element, nuclear extracts from HEK-293 cells transfected with either pcDNA or pHIF-1α&"' were incubated with the EMSA probe and electrophoresed. HIF-1 binding was increased greatly by hypoxia in the pcDNA-transfected cells and HIF-1α&"' inhibited this binding activity by 70 % (Figure 4C ). The lower bands ( Figure 4C , NS) represent the constitutive binding and non-specific binding. Super-shift by anti-HIF-1α antibody ( Figure 4C , SS) indicated that the upper band represents the HIF-1-DNA complex. From these results, we can postulate two possible mechanisms of HIF-1α&"'-induced suppression of endogenous HIF-1 activity : HIF-1α&"' may inhibit formation of the HIF-1 complex or it may weaken the DNA-binding affinity of endogenous HIF-1 to DNA. However, the second possibility is excluded here because HIF-1α&"' conserved the domains for ARNT binding and DNA binding. Moreover, since HIF-1α&"' is not translocated to the nucleus, it is unlikely that it affects the behaviour of HIF-1 located in the nucleus. Therefore, it is suggested that HIF-1α&"' inhibits the formation of the HIF-1 complex, but in what manner does this inhibition take place ? HIF-1α&"' may inhibit HIF-1 formation before HIF-1α and ARNT migrate from the cytosol to the nucleus.
Suppression of the hypoxic induction of HIF-1α-regulated genes
To confirm further that HIF-1α&"' functions like a dominantnegative mutant in response to hypoxia, we examined the mRNA levels of hypoxia-inducible genes such as VEGF, lactate dehydrogenase A (LDH A), enolase 1, aldolase A and phosphoglycerate kinase 1 (PGK 1) by semi-quantitative RT-PCR. In pcDNA-transfected cells exposed to hypoxia, all mRNAs of hypoxia-inducible genes were increased markedly compared with the normoxic control. In pHIF-1α&"'-transfected cells subjected to hypoxia, however, the hypoxic induction of these genes was reduced ( Figure 5 ). This result indicates that HIF-1α&"' competes with HIF-1α in terms of HIF-1 formation and activity, consequently suppressing the hypoxic induction of HIF-1-regulated genes.
Association of HIF-1α
516 and ARNT How does HIF-1α&"' inhibit endogenous HIF-1 activity ? We thought it possible that HIF-1α&"' associates with ARNT before the formation of the wild-type HIF-1α and ARNT complex in the nucleus. Our results demonstrated that the amount of ARNT protein in the nuclear extract was reduced by the overexpression of HIF-1α&"' ( Figure 6A ). However, the reduction of nuclear ARNT by HIF-1α&"' was not complete. Some untransfected cells seemed to remain and to show nuclear ARNT. To examine whether HIF-1α&"' associates with ARNT, immunoprecipitation of HA-tagged HIF-1α&"' was performed in the cytoplasmic fraction extracted from hypoxic cells using anti-HA antibody, followed by Western blotting with anti-ARNT antibody. As shown in Figure 6 (B), ARNT was co-precipitated with HIF-1α&"'. The lower band appears to be a short form of ARNT protein, resulting from proteolytic cleavage. These result suggests that ARNT is present in the cytoplasm and is physically associated with HIF-1α&"'. The association of HIF-1α&"' and ARNT in the cytoplasm may cause the reduction of nuclear ARNT and may be related to HIF-1α&"'-induced suppression of HIF-1 activity and the expression of hypoxiainducible genes.
DISCUSSION
In this report, we identified a new alternatively spliced variant of HIF-1α mRNA. This variant, HIF-1α&"', was expressed in all human cell lines tested, such as HEK-293, Hep3B, HeLa and SNU-601, but only negligibly in two murine cell lines. The variant differs from wild-type HIF-1α (HIF-1α)#') by lacking both exons 11 and 12, which introduces a frame shift resulting in a shorter form of HIF-1α, which was designated HIF-1α&"'. HIF-1α&"' was expressed stably even under hypoxic conditions, but was not translocated into the nucleus. The expressed HIF-1α&"' inhibited HIF-1 activity and reduced mRNA expression of the hypoxia-inducible genes that are regulated by HIF-1. HIF-1α&"' competed with endogenous and expressed wild-type HIF-1α, inhibiting the hypoxic activation of HIF-1. To our knowledge, this is the first report describing the presence of an endogous HIF-1α isoform functioning like a dominant-negative mutant. HIF-1α&"' could represent another useful tool in molecular biology as a dominant-negative isoform capable of suppressing cellular responses to hypoxia. Two alternatively spliced variants of human HIF-1α mRNA have been identified recently [18] . One of them translates a shorter form, composed of 736 amino acids (HIF-1α($'), which only has exon 14 missing, resulting in a frame shift and an immediate termination of translation. Since it conserves the whole of the ODD domain, it is well regulated by oxygen tension. Deletion of one of the two TADs causes the lower transactivation activity of HIF-1α($', which results in competition with overexpressed HIF-1α. However, the overexpressed HIF-1α($' markedly increases the hypoxic induction of reporter activity by up to 5-fold, compared with the hypoxic induction by endogenous HIF-1α. Although this HIF-1α($' is comparable with our HIF-1α&"' in terms of mRNA and protein structures, there are big differences between them. HIF-1α&"' lacks ODD, both TADs and NLS because of the deletion of exons 11 and 12. Therefore, HIF-1α&"' was more stable under normoxia and did not transactivate the EPO and VEGF promoters at all. Although it is uncertain whether HIF-1α($' works as a transcription factor or as a dominant-negative isoform, HIF-1α&"' was demonstrated to work as a dominant-negative isoform to inhibit endogenous HIF-1α, as shown in Figures 4 and 5 . The results also suggest that HIF-1α&"' can be employed as a molecule to suppress HIF-1-mediated hypoxic responses.
Endothelial PAS domain protein 1 (EPAS1) is another bHLH\ PAS transcription factor exhibiting high homology with HIF-1α and which is expressed preferentially in vascular endothelial cells. It also dimerizes with ARNT and then binds to the hypoxiaresponse element as HIF-1α does [23, 24] . Maemura et al. [25] found that a truncated EPAS1 (EPAS1%)&) lacking TAD functions as a dominant-negative mutant of EPAS1)(! and also competes with HIF-1α in a VEGF promoter assay. Unlike HIF-1α&"', EPAS1%)& is not a natural product but an artificially constructed one. No natural variant of EPAS1 capable of working like a dominant-negative mutant has yet been found. However, because the protein structure of EPAS1%)& is comparable with that of HIF-1α&"', it is a suitable model for comparative investigation into the function of HIF-1α&"'. The expressed EPAS1%)& showed similar effects on VEGF promoter activity and VEGF mRNA induction to those of HIF-1α&"'. It also competed with HIF-1α proteins, resulting in the inhibition of HIF-1 activity. Therefore, it is speculated that overexpressed EPAS1%)& may bind with ARNT, a common partner of HIF-1α and EPAS1, exhausting the unbound ARNT available for endogenous EPAS1 or HIF-1α. If so, the HIF-1α&"' possibly interacts with ARNT before the dimerization of HIF-1α and ARNT, and then interferes with the formation of functional HIF-1 complex.
How can cytosolic HIF-1α&"' interfere with the nuclear events of DNA binding and gene transactivation of HIF-1 ? To be able to bind to ARNT, HIF-1α&"' possibly interferes with the formation of HIF-1. Actually, a novel ARNT-interacting protein (AINT) has been reported to interfere with the formation of HIF-1 by sequestering ARNT in the cytoplasm [26] . AINT is a cytosolic protein having the property of physical association with ARNT. When the cytosolic protein was overexpressed, nuclear ARNT disappeared in the nucleus and was detected in the cytoplasm. Since HIF-1α&"' also has comparable properties in terms of cytoplasmic localization and association with ARNT, it is possible that HIF-1α&"', like AINT, inhibits nuclear translocation of ARNT. Recently, nuclear proteins other than ARNT have been reported to be sequestered in the cytoplasm by cytosolic proteins. For example, the nuclear translocation of β-catenin and Fe65 are inhibited by cadherins [27] and β-amyloid precursor protein [28] , respectively. These cytosolic proteins function as cytoplasmic anchoring sites, regulating the activities of the transcription factors. Based on this information, it is speculated that HIF-1α&"' as a dominant-negative isoform inhibits the formation of HIF-1 by sequestering ARNT in the cytoplasm.
HIF-1α&"' is not the only gene that generates dominantnegative splice variants. Recently, other dominant-negative isoforms have been reported, including a caspase-9 variant missing the catalytic site [29] , a STAT6 variant lacking the SH2 domain [30] , a vitamin D receptor isoform lacking the ligand-binding domain [31] and an oestrogen receptor isoform lacking the DNA-binding domain [32] . In general, these naturally occurring dominant-negative isoforms lose the critical domain(s) required for the functioning of the wild-type protein. HIF-1α&"' shares this common property as one of the dominant-negative isoforms. These isoforms are considered to maintain the metabolic balance by counteracting the overactions of their wild-type forms and may be ascribed to genetic or metabolic diseases. In this aspect, it is assumed that HIF-1α&"' may participate in the regulation of hypoxic gene expression as a counterpart of HIF-1α. To further address the physiological or pathological significance of the variant, a new method needs to be developed to specifically block its synthesis.
